Browse Trials

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor.</li> <li class="seamTextUnorderedListItem">The drug you receive will be determined by the results of your tumor's genomic test. </li> <li class="seamTextUnorderedListItem">Your may receive one or more of the following drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib (AKT inhibitor), Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Larotrectinib, Nivolumab, Osimertinib, Palbociclib (CDK inhibitor), Pertuzumab (anti-HER2), PI3K-beta Inhibitor GSK2636771, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab emtansine/T-DM1 (Kadcyla®) (antibody-drug conjugate (ADC)), Vismodegib</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ABL, ALK, BRAF, CDK4, CDK6, CSF-1R, EGFR, EGFR T790M, FGFR, FLT3, HER2 (ERBB2), KIT, MET, MEK, mTOR, NTRK fusions, PD-1, PDGFR, PI3K, PTCH1, PTEN loss, RET, ROS1, SMO, TRK, VEGFR, WEE1</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02465060' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match' target='_blank'>National Cancer Institute Study Website: NCI-Match</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/nci-match-eay131' target='_blank'>ECOG-ACRIN Cancer Research Group: NCI-Match</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy you receive will be selected based on your tumor's specific genetic profile.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">Your treatment may include one or more of the following: Abemaciclib, Afatinib, Crizotinib, Nivolumab, Ipilimumab, Olaparib, Palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib</li> <li class="seamTextUnorderedListItem">Targets or mutations: ALK, ATM, BRAF, BRAF V600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, HER2 (ERBB2), high mutational load and others, KIT, MET, MSI-H, mTOR, NRG1, PALB2, PDGFR, POLD1, POLE, RAF-1, RET, ROS1, TSC, VEGFR</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02693535' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.tapur.org/' target='_blank'>ASCO Study Website: TAPUR</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/conference-coverage/asco-2016/dr-edward-kim-on-ascos-tapur-trial' target='_blank'>OncLive: About TAPUR (video)</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-7684A is an experimental combination immunotherapy containing pembrolizumab and vibostolimab.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Vibostolimab is an experimental type of immunotherapy called a TIGIT inhibitor. Blocking TIGIT may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">5-fluorouracil (Fluracil®), cisplatin (Platinol®), and paclitaxel (Taxol®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05007106' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vibostolimab-pembrolizumab-mk-7684a?redirect=true' target='_blank'>National Cancer Institute: MK-7684A</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.annalsofoncology.org/article/S0923-7534(21)04776-1/fulltext' target='_blank'>Journal Article: Vibostolimab as Monotherapy or With Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/' target='_blank'>Merck Drug Information Page: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">225Ac-FPI-1966 and 111In-FPI-1967 are two experimental types of radiation therapy drugs called radiopharmaceuticals or radioactive drugs.</li> <li class="seamTextUnorderedListItem">Vofatamab is an experimental type of targeted therapy called an FGFR3 inhibitor. Targeting FGFR3 may slow or stop cancer cell growth.</li> <li class="seamTextUnorderedListItem">Your tumor does not need to have an FGFR3 mutation.</li> <li class="seamTextUnorderedListItem">This is a <span class="highlight">basket</span> trial, which means this trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FGFR3</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05363605' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://fusionpharma.com/fusion-pipeline/' target='_blank'>Fusion Pharmaceuticals Drug Information Page: [225Ac]-FPI-1966</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy' target='_blank'>National Cancer Institute: Radiopharmaceuticals</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.annalsofoncology.org/article/S0923-7534(19)59133-5/fulltext' target='_blank'>Abstract: Clinical Activity of Vofatamab with Pembrolizumab for Metastatic Urothelial Carcinoma</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is an anti-HER2-targeted therapy approved for use in HER2 positive breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy routinely used for HER2 positive breast cancer, but its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: HER2/ERBB</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04579380' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tukysa.com/?&utm_source=GOOGLE&utm_medium=cpc&utm_campaign=GS_Brand_Fullsite_Alone_PI&utm_content=General_EX&utm_term=tucatinib&gclsrc=ds&gclid=CjwKCAiA9bmABhBbEiwASb35V8_ibwE-Ey-u91KsJCshbmkozNCJ60FlvCmi5bs3npzhPRr6KigNdBoC4VgQAvD_BwE&gclsrc=' target='_blank'>Seagen Drug Information Page: Tukysa® (Tucatinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Trastuzumab' target='_blank'>Wikipedia: Trastuzumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer' target='_blank'>FDA: FDA Approves Tucatinib for Patients with HER2-Positive Metastatic Breast Cancer</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A group of doctors will make a treatment decision for you by studying your tumor's genetic profile (this is called genomic testing).</li> <li class="seamTextUnorderedListItem">The group of doctors will choose 2 drugs out of 35 to give to you. </li> <li class="seamTextUnorderedListItem">The types of drugs available include: targeted therapies, immunotherapies, and chemotherapies. </li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> studies enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ABL, BCL2, BRAF, CDK4, CDK6, COX-2, CSF-1R, CTLA-4, EGF, EGFR, FGFR, FLT3, HDAC, HER2 (ERBB2), JAK1/2, KIT, MEK, MET, mTOR, PARP, PD-1, PDGFR, PI3Kdelta, RAF, RET, VEGF, VEGF ligand, VEGFR</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03878524' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ohsu.edu/spatial-systems-biomedicine-center/serial-measurements-molecular-and-architectural-responses' target='_blank'>Oregon Health & Science University: SMMART program</a> </li><li class='seamTextUnorderedListItem'><a href='https://news.ohsu.edu/2018/11/16/making-cancer-clinical-trials-smmart' target='_blank'>Oregon Health & Science University NEWS: Making cancer clinical trials SMMART</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ELU001 is a new type of targeted therapy called C'Dot drug conjugate (CDC). </li> <li class="seamTextUnorderedListItem">Drug conjugates deliver the drug directly to the tumor. </li> <li class="seamTextUnorderedListItem"><span class="highlight">Basket</span> studies enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer whose tumors overexpress Folate Receptor Alpha (FRα).</li> <li class="seamTextUnorderedListItem">Targets or mutations: Folate Receptor Alpha (FRα)</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05001282' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.globenewswire.com/news-release/2021/09/17/2299166/0/en/Elucida-Oncology-Announces-First-Patient-Dosed-in-Phase-1-2-Study-of-ELU001-in-Patients-with-Advanced-Recurrent-or-Refractory-Cancers-Overexpressing-Folate-Receptor-Alpha-FR%CE%B1.html' target='_blank'>Elucida Oncology Press Release: ELU001</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lurbinectedin (Zepzelca®) is a chemotherapy approved for the treatment of other types of cancer. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. It is enrolling people with other types of cancer based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HRD</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05126433' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zepzelca.com/' target='_blank'>Jazz Pharmaceuticals Drug Information Page: Lurbinectedin (Zepzelca®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/lurbinectedin-makes-a-splash-in-second-line-sclc' target='_blank'>OncLive: Lurbinectedin (Zepzelca®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular profiling of a tumor may identify genetic mutations or biomarkers that suggest the tumor is likely to respond to a currently available targeted therapy. </li> <li class="seamTextUnorderedListItem">It is not known if choosing metastatic breast cancer treatment based on the tumor's molecular profile is more effective than the current standard of care. </li> <li class="seamTextUnorderedListItem">All people who enroll in this study will have molecular profiling performed on a biopsy of their tumor. </li> <li class="seamTextUnorderedListItem">If there is no mutation or biomarker found, you will receive the treatment the doctor determines is the best option. </li> <li class="seamTextUnorderedListItem">If a mutation or biomarker is found and there is an FDA-approved drug for the tumor type, you will be offered that treatment. </li> <li class="seamTextUnorderedListItem">If there is a mutation or biomarker found but no FDA-approved drug that targets it, you will be randomly assigned to either a targeted therapy or the standard of care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: vary based on test results.</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02152254' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825646/' target='_blank'>Journal Article: Molecular Profiling for Breast Cancer</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Navicixizumab is an experimental targeted therapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Navicixizumab targets both DLL4 and VEGF.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">An electrocardiogram (ECG) test records electrical signals in your heart.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05453825' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncxerna.com/programs/' target='_blank'>OncXerna Theraputics Drug Information Page: Navicixizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/taxol' target='_blank'>Breastcancer.org: Paclitaxel (Taxol®)</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most genetic mutations found in cancer cells are not passed down from parents (inherited), but occur when the cells make mistakes when they divide.</li> <li class="seamTextUnorderedListItem">Most cancers have many mutations.</li> <li class="seamTextUnorderedListItem">Some of these mutations help drive the tumor's growth, while others are just bystanders.</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01775072' target='_blank'>ClinicalTrials.gov</a> </li></ul>

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy drug is pembrolizumab (Keytruda®). </li> <li class="seamTextUnorderedListItem">Keytruda® is a type of immunotherapy drug called a PD-1 inhibitor. It gets the immune system to go after cancer cells by blocking a protein called programmed cell death (PD-1). </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancers.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1/2 tumor (not inherited), POLE, POLD1</li></ul>

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03428802' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ascopost.com/issues/july-10-2017/pembrolizumab-moving-forward-in-triple-negative-breast-cancer/' target='_blank'>ASCO: Keytruda for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/articles/parp-inhibitor-may-prolong-survival-in-metastatic-brcapositive-breast-cancer' target='_blank'>Cure Today: Parp Inhibitor May Prolong Survival</a> </li></ul>